Video

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Related Content
Douglas W. Sborov, MD, MS
October 28th 2024

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Scott A. Armstrong, MD, PhD, President, Dana-Farber/Boston Children's
October 25th 2024

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

Daniel J. DeAngelo, MD, PhD, of Dana-Farber Cancer Institute
October 25th 2024

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis